Hydroxyurea Reduced Mortality for Children With Sickle Cell Anemia
A 10-year study in sub-Saharan Africa revealed that a higher dose of the oral medication Hydroxyurea improved survival and growth outcomes in children with sickle cell anemia.
Category: Intl’ Pharmaceuticals
Intl' Pharmaceuticals
Latest
Hydroxyurea Reduced Mortality for Children With Sickle Cell Anemia
A 10-year study in sub-Saharan Africa revealed that a higher dose of the oral medication Hydroxyurea improved survival and growth outcomes in children with sickle cell anemia.
Read More
Inhaled Nanomedicine Targets Tuberculosis in the Lungs
A new delivery system allows four standard tuberculosis medications to be inhaled directly into the respiratory tract, potentially reducing side effects and improving treatment adherence.
Read More
FDA, EMA Accept Filings for Teva Xolair Biosimilar
The US FDA and the European Medicines Agency (EMA) accepted regulatory filings for Teva Pharma’s biosimilar candidate to Xolair (omalizumab).
Read More
EU Approves EURneffy Adrenaline Nasal Spray for Young Children
The European Commission authorized the EURneffy 1 mg nasal spray for pediatric patients who weigh between 15 and 30 kg and are at risk of severe allergic reactions.
Read More
FDA, European Commission Grant Orphan Drug Designation for New IPF Treatment
Deupirfenidone showed a slower rate of lung function decline compared to existing therapies in a...
Read More
EU Committee Recommends EURneffy Adrenaline Nasal Spray for Younger Children
The European Medicines Agency’s CHMP recommended expanding the marketing authorization for EURneffy to include a 1 mg dose.
Read More
WHO: Opioid Agonist Treatment an Essential Health Service
The World Health Organization says opioid agonist maintenance treatment (OAMT) is a cost-effective intervention that reduces mortality and morbidity.
Read More
Epinephrine Nasal Spray Approved in China
The National Medical Products Administration (NMPA) in China granted approval for neffy 2 mg (epinephrine nasal spray) for the emergency treatment of Type 1 allergic reactions in adults and children weighing 30 kg or more.
Read More
European Commission Approves Brinsupri for Non-CF Bronchiectasis
Brinsupri (brensocatib) is now the first and only authorized treatment for non-cystic fibrosis bronchiectasis in the EU for patients 12 and older with recurrent exacerbations.
Read More
Tezspire Approved in EU for CRSwNP
The European Commission approved Tezspire (tezepelumab) as an add-on therapy with intranasal corticosteroids for adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP).
Read More
EU Panel Recommends Tezspire for Chronic Rhinosinusitis with Nasal Polyps
AstraZeneca and Amgen’s Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Read More
EU Panel Recommends Approval of Enflonsia for RSV Prevention
The European Medicines Agency’s CHMP recommended Enflonsia to prevent RSV lower respiratory tract disease in neonates and infants during their first RSV season.
Read More
Epinephrine Nasal Spray Approved in Japan
Regulators in Japan have cleared neffy epinephrine nasal spray for emergency use in adults and children for life-threatening allergies.
Read MorePositive CHMP Opinion for Comirnaty LP.8.1-adapted COVID-19 Vaccine
The European Medicines Agency’s CHMP recommended marketing authorization for the Pfizer/BioNTech’s LP.8.1-adapted monovalent COVID-19 vaccine (Comirnaty LP.8.1).
Read More
UK Approves EURneffy Nasal Spray
The UK MHRA has authorized EURneffy for the emergency treatment of anaphylaxis in adults and children weighing 30kg or more.
Read More
NHS England to Offer Alyftrek for Cystic Fibrosis
England’s National Institute for Health and Care Excellence issued a positive final draft recommendation for Vertex Pharma’s Alyftrek CFTR modulator, which will now be available via the National Health Service (NHS).
Read More
European Commission Approves Vertex’s Alyftrek Once-Daily CFTR Modulator
Alyftrek is a triple combination CFTR modulator comprised of deutivacaftor, tezacaftor and vanzacaftor.
Read More
Positive Results for Viromed VAP Therapy
Viromed Medical AG is reporting positive results for its PulmoPlas therapy in the treatment of ventilator-associated pneumonia (VAP) in intensive care unit patients.
Read More
Inhaled COVID Vaccine Begins Recruitment for Phase 2 Trial
The phase 2 The AeroVax study will evaluate the safety and effectiveness of a novel inhaled COVID-19 vaccine.
Read More
UK’s NICE Recognizes Cytisine as Key Smoking Cessation Treatment
The 2025 NICE update includes Cytisine as a recommended smoking cessation treatment after its UK launch and a review of clinical evidence.
Read More
Growing Inequalities in UK Child Vaccination Rates
Inequalities in childhood vaccination are widening in England, with uptake rates of five key vaccines consistently lower in young children living in areas of higher deprivation from 2019 to 2023.
Read More
Eli Lilly’s Mounjaro Doesn’t Need Separate Approval for Sleep Apnea, Says EMA
The EMA has determined that Mounjaro’s existing weight management approval includes its benefits for treating obstructive sleep apnea, eliminating the need for a separate application for an OSA indication.
Read More
WHO Authorizes First Mpox Vaccine for Children Over Age 1
The WHO has granted Emergency Use Listing for the LC16m8 mpox vaccine, making it the second mpox vaccine to be supported by WHO and the first for children over age 1.
Read More
Epilepsy Drug Improves Sleep Apnea Symptoms in Trial
People taking the drug had fewer pauses in their breathing and higher levels of oxygen in their blood during sleep.
Read More